Previous close | 0.3500 |
Open | 0.1500 |
Bid | 0.1000 |
Ask | 0.2000 |
Strike | 2.00 |
Expiry date | 2024-06-21 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | 259 |
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Salary of US$982.9k is part of CEO...
Coherus BioSciences ( NASDAQ:CHRS ) First Quarter 2024 Results Key Financial Results Revenue: US$77.1m (up 138% from 1Q...